2186 — Luye Pharma Income Statement
0.000.00%
Last trade - 00:00- HK$11.38bn
- HK$17.19bn
- CNY6.31bn
Annual income statement for Luye Pharma, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 5,200 | 5,982 | 6,143 | 6,061 | 6,308 |
| Cost of Revenue | |||||
| Gross Profit | 3,397 | 4,141 | 4,204 | 4,044 | 4,163 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 4,876 | 4,841 | 4,768 | 4,660 | 4,646 |
| Operating Profit | 324 | 1,141 | 1,375 | 1,402 | 1,663 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -74.6 | 670 | 700 | 839 | 945 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -145 | 583 | 539 | 645 | 706 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -134 | 605 | 533 | 472 | 619 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -134 | 605 | 533 | 472 | 619 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.01 | 0.191 | 0.144 | 0.126 | 0.162 |